Neoadjuvant therapy with lenvatinib improves resectability in advanced thyroid cancer, suggesting refined molecular profiling could enhance treatment outcomes.
Neoadjuvant lenvatinib enabled conversion to resectability and meaningful surgical de-escalation in selected patients with LATC, with acceptable toxicity. CT-based complexity scores were useful tools for patient selection. Prospective multicenter studies integrating molecular profiling are needed to refine indications and optimal treatment duration.
No takes yet. Share an insight, caveat, or question.
Santivañez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: